Filing Flows › Industrials › bioAffinity Technologies (BIAF)
bioAffinity Technologies (BIAF) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 6, 2026 · bioAffinity Technologies (BIAF) Q3 2026 earnings results →
Q3 2026 Revenue down 26% year over year to $1.1M · 493¢ of every $1 of revenue lost · operating margin -328.0%
bioAffinity Technologies made $1.1M in Q3 2026 (-26% Y/Y): Health Care, Patient Service $863K, Histology Service Fees $190K, Medical Director Fees $17K. Operating margin -328.0%, net loss $5.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.1M in Q3 2026, down 26% year over year and down 29% from the previous quarter. Health Care, Patient Service was the largest line at 81% of revenue. Health Care, Patient Service lost $309K year over year (down 26%), 82% of the total change.
Operating costs exceeded revenue by $3.5M, an operating margin of -328.0%. Total costs grew 23% against a revenue fall of 26%. The fastest-growing cost line was SG&A (+25%). The quarter ended with a net loss of $5.3M, wider than the previous quarter's $3.4M loss.
Operating cash flow was −$3.9M. Non-cash charges added back $67K of depreciation and amortization and $139K of share-based compensation. Working capital and other items added $1.2M. Capital expenditures of $77K exceeded it, leaving free cash flow of −$3.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 6, 2026 | $1.1M | -26% | -328.0% | −$5.3M | −$3.9M |
| Q2 2026 | 10-Q | Aug 7, 2026 | $1.5M | +19% | -220.8% | −$3.4M | −$3.2M |
| Q1 2026 | 10-Q | May 11, 2026 | $1.4M | -27% | -267.6% | −$3.6M | −$3.2M |
| Q4 2025 | 10-K | Mar 16, 2026 | $1.6M | -28% | -196.9% | −$3.1M | −$2.6M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $1.4M | -38% | -158.6% | −$5.1M | −$2.5M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $1.3M | -47% | -198.2% | −$4.1M | −$2.6M |
| Q1 2025 | 10-Q | May 15, 2025 | $1.9M | -23% | -141.7% | −$2.7M | −$1.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About bioAffinity Technologies
We develop noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Our first commercial diagnostic test, CyPath ® Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. CyPath ® Lung addresses the need for noninvasive detection of early-stage lung cancer with the proven ability to detect the leading cancer killer at its curative Stage 1A. Lung cancer is the leading cause of cancer-related deaths worldwide. Physicians order CyPath ® Lung to assist in their assessment of patients who are at high risk for lung cancer.
In its own words, from its 10-K, filed Mar 16, 2026.
bioAffinity Technologies against its Services-Commercial Physical & Biological Research peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -26% against the peers' median +8%. Operating margin: -328.0% against the peers' median 12.9%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BIAF bioAffinity Technologies | Q3 2026 | $1.1M | -26% | -328.0% |
| IQV IQVIA Holdings | Q3 2026 | $4.4B | +8% | 12.9% |
| INCY Incyte | Q3 2026 | $1.6B | +14% | -45.5% |
| CRL Charles River Laboratories International | Q3 2026 | $983M | -2% | 20.6% |
| MEDP Medpace Holdings | Q3 2026 | $716M | +8% | 23.1% |
| NRC NRC Health | Q3 2026 | $38.4M | +11% | 23.2% |
| MXCT Maxcyte | Q2 2026 | $7.3M | -14% | -140.7% |
| FOXO Foxo Technologies | Q2 2026 | $4.7M | -10% | 185.5% |
| OABI OmniAb | Q3 2026 | $4.0M | +78% | -409.9% |
Source: bioAffinity Technologies 10-Q on SEC EDGAR · CIK 1712762 · Services-Commercial Physical & Biological Research
Guidance and outlook
More on BIAF
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- bioAffinity Technologies guidance history: guided vs reported
- bioAffinity Technologies R&D spending by quarter
- bioAffinity Technologies Health Care, Patient Service revenue by quarter
- bioAffinity Technologies Histology Service Fees revenue by quarter
- bioAffinity Technologies Medical Director Fees revenue by quarter